Trial reportNeuro-oncology2022
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.
Trial report in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Systemic therapy in the treatment of recurrent or refractory intracranial meningiomas: A systematic review and individual patient data meta-analysis.Neurosurgical review · 2026Pooled it
- Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.Neuro-oncology · 2025Pooled it
- European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.Neuro-oncology · 2025Guideline
- Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma.CNS neuroscience & therapeutics · 2025Trial
- 3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.Neuro-oncology · 2024Trial
- Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539.Neuro-oncology · 2023Trial
- Temporally-Modulated Pulsed Radiation Therapy for Large-Volume Reirradiation of Recurrent Meningioma.Advances in radiation oncology · 2026Article
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- Meningioma microenvironment harbors a rich immune landscape that evolves with biological state.Neuro-oncology · 2026Article
- Radiotherapy for Meningiomas: Molecular, Imaging, and Therapeutic Advances.Current oncology reports · 2026Review
- Targeted and Personalized Therapy for Difficult Benign Brain Tumors: A Review.Journal of personalized medicine · 2026Review
- Profiling of rare immune cell populations and integrative analysis identify immune ecotypes in newly diagnosed meningiomas.Acta neuropathologica communications · 2026Article
- PD-L1 positivity predicts a unique hyperaggressive tumor group within MenG C meningiomas.JNCI cancer spectrum · 2026Article
- Translation and Validation of the Neurologic Assessment in Neuro-Oncology Scale into Indonesian (NANO-Ina).Asian Pacific journal of cancer prevention : APJCP · 2026Article
- STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways.Nature communications · 2026Article
- Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma.Acta neuropathologica communications · 2026Article
- Combined SSTR2-targeted Analogue withFrontiers in oncology · 2026Article
- Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningioma.Neuro-oncology · 2025Article
- Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells.Journal of neuro-oncology · 2025Article
- Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad scope and implementation-A progress report.Neuro-oncology · 2025Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
30 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundProgrammed death ligand 1 (PD-L1) contributes to tumor immunosuppression and is upregulated in aggressive meningiomas. We performed a phase II study of nivolumab, a programmed death 1 (PD-1) blocking antibody among patients with grade ≥2 meningioma that recurred after surgery and radiation therapy.
methodsTwenty-five patients received nivolumab (240 mg biweekly) until progression, voluntary withdrawal, unacceptable toxicity, or death. Tumor mutational burden (TMB) and quantification of tumor-infiltrating lymphocytes (TIL) were evaluated as potential immunocorrelative biomarkers. Change in neurologic function was prospectively assessed using the Neurologic Assessment in Neuro-Oncology (NANO) scale.
resultsEnrolled patients had multiple recurrences including ≥3 prior surgeries and ≥2 prior courses of radiation in 60% and 72%, respectively. Nivolumab was well tolerated with no unexpected adverse events. Six-month progression-free survival (PFS-6) rate was 42.4% (95% CI: 22.8, 60.7) and the median OS was 30.9 months (95% CI: 17.6, NA). One patient achieved radiographic response (ongoing at 4.5 years). TMB was >10/Mb in 2 of 15 profiled tumors (13.3%). Baseline TIL density was low but increased posttreatment in 3 patients including both patients with elevated TMB. Most patients who achieved PFS-6 maintained neurologic function prior to progression as assessed by NANO.
conclusionNivolumab was well tolerated but failed to improve PFS-6, although a subset of patients appeared to derive benefit. Low levels of TMB and TIL density were typically observed. NANO assessment of neurologic function contributed to outcome assessment. Future studies may consider rationally designed combinatorial regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.